StockNews.AI
VOR
StockNews.AI
3 hrs

Vor Bio Appoints Navid Z. Khan, Ph.D.

1. Dr. Khan appointed as Chief Medical Affairs Officer at Vor Bio. 2. He has led over 40 development programs in relevant therapeutic areas. 3. His experience includes successful launches of significant autoimmune therapies. 4. Vor is advancing telitacicept through Phase 3 clinical development. 5. The company's goal is to transform autoimmune disease treatment globally.

7m saved
Insight
Article

FAQ

Why Bullish?

The appointment of Dr. Khan enhances Vor's leadership in developing therapies, similar to past biotech success stories that improved stock valuations after leadership changes.

How important is it?

Dr. Khan's experience directly aligns with Vor's goals, making this leadership shift significant for investors.

Why Long Term?

Long-term impact expected as Dr. Khan establishes his strategies and leads upcoming product launches, transforming Vor's market position over time.

Related Companies

ARGXSRPTAKUS
Dr. Khan brings decades of global medical affairs, commercial, and scientific leadership across multiple therapeutic areas including seven successful product launches September 23, 2025 08:00 ET  | Source: Vor Biopharma CAMBRIDGE, Mass., Sept. 23, 2025 (GLOBE NEWSWIRE) -- Vor Bio (Nasdaq: VOR), a clinical-stage biotechnology company dedicated to transforming the treatment of autoimmune diseases, today announced the appointment of Navid Z. Khan, Ph.D., as Chief Medical Affairs Officer. Dr. Khan joins Vor Bio with over two decades of experience spanning medical affairs, commercial, and R&D functions. He has overseen more than 40 development programs in neurology, immunology, and infectious diseases, and successfully guided seven U.S. and global product launches in rare neurology and immunology indications. Most recently, Dr. Khan was Head of Neuromuscular Therapeutic Area, Medical Affairs at argenx, where he led integrated medical strategy and execution for four launches of VYVGART® and VYVGART Hytrulo®, including two for generalized myasthenia gravis (gMG). “Navid is an exceptional leader with a proven track record of building world-class medical affairs organizations and executing multiple high-impact product launches,” said Jean-Paul Kress, M.D., Chief Executive Officer and Chairman of the Board of Vor Bio. “His deep scientific expertise, combined with his ability to connect with patients, physicians, and global stakeholders, will be invaluable as we advance telitacicept and shape our broader autoimmune portfolio.” “I am thrilled to join Vor Bio at such an exciting time,” said Dr. Khan. “Vor has the potential to transform the treatment of autoimmune diseases with telitacicept and beyond. I look forward to working with the talented team to build a best-in-class medical affairs function that ensures strong scientific exchange, evidence generation, and meaningful engagement with the patient and physician communities worldwide.” Earlier in his career, Dr. Khan held senior leadership positions at Akouos Inc. and Sarepta Therapeutics, where he played a pivotal role in the launch of three Duchenne muscular dystrophy therapies - EXONDYS 51®, VYONDYS 53®, and AMONDYS 45® - and helped transform Sarepta’s Medical Affairs organization in preparation for a wave of gene therapy programs. He also held roles of increasing responsibility at EMD Millipore over more than a decade, spanning R&D, viral vector and vaccine strategy, and commercial leadership. Dr. Khan earned his Ph.D. in Biomedical Engineering and Biotechnology from the University of Massachusetts, Lowell, and his B.S. in Biochemistry and Molecular Biology from the University of Massachusetts, Amherst. About Vor BioVor Bio is a clinical-stage biotechnology company transforming the treatment of autoimmune diseases. The company is focused on rapidly advancing telitacicept, a novel dual-target fusion protein, through Phase 3 clinical development and commercialization to address serious autoantibody-driven conditions worldwide. For more information visit www.vorbio.com. Forward-Looking StatementsThis press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. The words “aim,” “anticipate,” “can,” “continue,” “could,” “design,” “enable,” “expect,” “initiate,” “intend,” “may,” “on-track,” “ongoing,” “plan,” “potential,” “should,” “target,” “update,” “will,” “would,” and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Forward-looking statements in this press release include Vor Bio’s statements regarding Vor Bio’s potential to transform the treatment of autoimmune diseases with telitacicept and beyond and other statements that are not historical fact. Vor Bio may not actually achieve the plans, intentions, or expectations disclosed in these forward-looking statements, and you should not place undue reliance on these forward-looking statements. Actual results or events could differ materially from the plans, intentions and expectations disclosed in these forward-looking statements as a result of various factors. These and other risks are described in greater detail under the caption “Risk Factors” included in Vor Bio’s most recent annual or quarterly report and in other reports it has filed or may file with the Securities and Exchange Commission. Any forward-looking statements contained in this press release speak only as of the date hereof, and Vor Bio expressly disclaims any obligation to update any forward-looking statements, whether because of new information, future events or otherwise, except as may be required by law. Media & Investor Contacts:Carl Mauchcmauch@vorbio.com Sarah Spencerinvestors@vorbio.com

Related News